Compare Amylx Pharmaceuticals Inc (AMLX) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.59 (market cap $2.64B), while iShares 3 7 Year Treasury Bond ETF trades at $116.45. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | IEI | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Fixed Income |
52-Week High | $24.19 | $120.72 |
52-Week Low | $7.82 | $116.16 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% on the day, amid a bearish technical signal from moving averages and neutral oscillators. The ETF maintains a steady dividend payout schedule, with recent distributions around $0.37 per share. Market sentiment is influenced by rising Treasury yields and inflation concerns, as highlighted in recent financial news.
The outlook for IEI is cautious due to potential Federal Reserve rate hikes and inflation pressures, which could pressure bond prices. Opportunities lie in its government backing and lower volatility, but risks include interest rate sensitivity and macroeconomic shifts affecting yield curves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
